Stevens-Johnson syndrome (SJS) is not curable in the traditional sense, but it is survivable and treatable. There is no drug or therapy that reverses the condition once it starts. Instead, treatment focuses on stopping the trigger, supporting the body while damaged skin regrows, and managing complications. Most people recover, though it can take weeks to months, and some experience lasting effects on their eyes, skin, or other areas.
What SJS Does to the Body
SJS is a rare, severe reaction, usually triggered by a medication, that causes the top layer of skin to die and shed. It typically begins with flu-like symptoms, then a painful rash that spreads and blisters. The body essentially attacks its own skin and mucous membranes (the moist linings of the mouth, eyes, and genitals). A more severe form, called toxic epidermal necrolysis (TEN), involves more than 30% of the body’s skin surface.
Because the skin is the body’s barrier against infection and fluid loss, SJS is a medical emergency. Nearly all patients require hospitalization, and many are treated in burn units where staff are experienced with large-scale skin damage.
Why There Is No “Cure”
SJS is not a chronic disease you manage over time. It’s an acute crisis. Once the immune system begins attacking the skin, no medication can instantly stop the damage or regrow what’s been lost. The body has to heal on its own, much like a severe burn. Treatment is entirely supportive: remove the drug that caused it, protect the raw skin from infection, manage pain, and keep the patient nourished and hydrated while new skin forms.
This distinction matters. “Curable” implies a treatment that eliminates the disease. With SJS, the goal is survival and minimizing damage while the episode runs its course. The good news is that for most people, the skin does regrow and the acute phase ends.
What Treatment Looks Like
The first and most critical step is identifying and stopping the medication that triggered the reaction. Every hour the offending drug stays in the system, more skin can be affected. Common triggers include certain anti-seizure medications, antibiotics, and gout drugs.
Once in the hospital, wound care is the central focus. Unlike burns, doctors often leave detached skin in place after draining blister fluid. The reasoning is that some of those loosened skin cells may still be alive and can help new skin grow underneath. Blisters are drained because the fluid inside contains inflammatory compounds that can worsen the damage if left in contact with surrounding tissue. Wounds are then gently cleaned and covered with protective dressings.
Fluid replacement is important but handled differently than with burn patients. Doctors adjust fluids based on each patient’s needs rather than using aggressive resuscitation protocols. Nutrition is also a priority. If a patient can eat, they’re encouraged to do so. If mouth sores make swallowing impossible, a feeding tube is placed to ensure adequate calorie intake during healing.
Some hospitals use immune-suppressing medications to try to slow the attack on the skin. Research comparing two common options found that one (cyclosporine) showed a meaningful survival advantage over another (intravenous immunoglobulin), though these treatments remain a subject of ongoing clinical debate and aren’t universally standardized.
How Long Recovery Takes
Hospital stays vary widely depending on severity. In a study of 111 patients, roughly half stayed between 14 and 28 days. About a quarter were discharged in under two weeks, while another quarter required more than 28 days of care. The healing timeline after discharge can extend further, with full recovery sometimes taking months.
Mucosal tissue (inside the mouth, for example) tends to heal faster than skin because it has a quicker cell turnover and better blood supply. Skin regrowth is slower and depends on how much surface area was affected.
Survival Rates and Severity
Doctors use a scoring system called SCORTEN to predict how serious a case will be. It considers factors like the patient’s age, heart rate, how much skin is affected, and certain blood markers. For patients with zero or one risk factor, mortality is around 3.2%. At two risk factors, it rises to about 12%. Three risk factors push mortality to roughly 35%, and at five or more, survival becomes unlikely.
Being under 40, having less than 10% of skin affected, and having no underlying cancer are all associated with better outcomes. This is why early recognition and rapid hospital admission matter so much.
Long-Term Effects After Recovery
Even after the skin heals, SJS can leave lasting problems. The eyes are particularly vulnerable. A Japanese national survey found that about 14% of SJS survivors experienced long-term visual disturbance or chronic eye dryness. Scarring of the cornea and the inner eyelid lining can occur, sometimes requiring years of follow-up care with an ophthalmologist.
Skin changes are also common. Survivors may notice permanent discoloration, scarring, or changes in how their nails grow. Some people develop ongoing sensitivity in areas where the skin was most severely affected. Scarring in the mouth or genital area can also cause chronic discomfort.
Preventing It From Happening Again
Avoiding the drug that caused SJS is the single most important thing a survivor can do. Recurrence happens in up to 18% of cases, and re-exposure tends to cause a more severe episode. In documented cases, a single dose of the same drug class was enough to trigger a full-blown recurrence. A second episode is also more likely to be fatal than the first.
Survivors should carry a list of the triggering medication and related drugs, and make sure every healthcare provider they see is aware. Drugs in the same chemical family can also cause a reaction, so avoidance often extends beyond the single medication.
Genetic Testing Can Prevent First Episodes
For certain medications, a simple genetic test before the first prescription can identify people at high risk. The best-established example involves carbamazepine, an anti-seizure drug. People who carry a specific genetic variant called HLA-B*15:02, which is more common in people of Southeast Asian descent, have a significantly elevated risk of developing SJS if they take carbamazepine. Clinical guidelines now strongly recommend that anyone who carries this variant should not be prescribed carbamazepine at all and should be given an alternative medication instead.
A similar genetic marker, HLA-A*31:01, is also linked to carbamazepine-triggered SJS and related severe skin reactions. Genetic screening for other high-risk drugs, like the gout medication allopurinol, follows the same principle: test before prescribing, and choose a different drug if the patient carries a risk-associated variant. These tests are not yet routine for every medication, but they represent the most effective form of prevention currently available.